Skip to main content

Huntington's Disease clinical trials at UC Davis

3 research studies open to eligible people

Showing trials for
  • A study following patients with Huntington's Disease over time

    “Help us learn more about Huntington's Disease”

    open to eligible people ages 18 years and up

    Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries—REGISTRY in Europe, and COHORT in North America and Australasia—while also expanding to include sites in Latin America. More than 20,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit to learn more.

    Sacramento, California and other locations

  • A Study of the Safety and Tolerability of Experimental WVE-120102 For Huntington's Disease

    open to eligible people ages 25-65

    PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120102 in adult patients with early manifest Huntington's disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362331 (SNP2).

    Edmonton, Alberta and other locations

  • Tolerability, safety, and activity of experimental medicine, SRX246 in irritable patients with Huntington's Disease

    “Does experimental medicine, SRX246 help treat irritability in Huntington's Disease patients?”

    open to eligible people ages 18 years and up

    This study evaluates the tolerability, safety and activity of SRX246 in the treatment of irritability in patients with Huntington's disease. Two-thirds of all participants will receive SRX246, while the other third will receive a placebo.

    Sacramento, California and other locations